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ABSTRACT
Photodynamic therapy (PDT) is a treatment modality for various illnesses,
including some types of cancer. Lung cancer is the leading cause of cancer death in the
United Sates. The prevalence of lung cancer in certain gender, racial, ethnic, and
socioeconomic groups add to existing health disparities in the United States. For this
reason, it is necessary to address the social determinants underlying lung cancer
disparities, as well as improve treatment options. These treatment options should be cost
effective, convenient, and increase survival rates. This research focused on synthesizing
novel water-soluble porphyrin compounds for use as photosensitive agents in PDT for
the treatment of lung cancer. Three novel water-soluble compounds were synthesized.
The compounds were then purified and characterized prior to being tested on an A549
non-small cell lung cancer line in vitro.

BACKGROUND
Introduction
One in every three people in the United States is affected by cancer.1 Cancer is
caused when cells that are older or abnormal do not die as they should. As a result, the
older or abnormal cell keeps making copies of itself that eventually crowd normal tissues.
Certain types of cancer, such as lung cancer, begin in one part of the body and spread, or
metastasize to other parts of the body. Lung cancer is a type of solid tumor cancer.1
Lung cancer is the second most common cancer and leading cause of cancer death
in the United States.2 Two types of lung cancer are small cell lung cancer (SCLC) and
non-small cell lung cancer (NSCLC). They both cause similar symptoms and are capable
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of metastasizing. Some patients can be diagnosed with both SCLC and NSCLC.
Anatomically, the cells for NSCLC are larger under a microscope. SCLC tends to be
more aggressive and spread more rapidly, but NSCLC is more common. Around 84% of
all lung cancers are non-small cell lung cancer.3 NSCLC has a five year survival rate of
23%, while SCLC has a five year survival rate of 6%.3 Adenocarcinoma is a type of
NSCLC which occurs in the outer part of the lung beginning in the mucus making cells
that line the alveoli.

Lung Cancer Disparities
With the ongoing COVID-19 pandemic, disparities in healthcare have begun to
gain more attention.4 This recent gain in attention is due largely to the recognition of
disparities experienced by certain racial and ethnic minority groups in regard to COVID19 illnesses, treatment, and healthcare.4 However, healthcare disparities are not a new
problem. The COVID-19 pandemic has simply helped to bring existing healthcare
disparities to light. Inequalities that exist in the social determinants of health are
responsible for these disparities. Some of these determinants include neighborhood and
physical environment, health and healthcare, occupation and job conditions, income, and
education. Additional factors such as racial discrimination and chronic stress also
influence these social determinants of health.
The disparities that exist for lung cancer vary, but factors like gender and
ethnicity can put people at a health disadvantage.4 Lung cancer is ranked first for
women’s related cancer deaths, and is responsible for 26% of all cancer deaths among
women.5 Many incidents of lung cancer are due to a history of smoking. Smoking is one
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of the underlying determinants of health disparities that exist for lung cancer. For
example, Native Americans have some of the highest prevalence of smoking and lung
cancer is one of the leading causes of death for Native Americans.6
Lung cancer is highly prevalent in Black, Asian, and other minority groups, as
well as in women. Adenocarcinomic NSCLC is the most common form of lung cancer
and is diagnosed mainly in people who smoke or have smoked. It is also more commonly
diagnosed in younger adults and in women.7 For these reasons, it is important to address
both the determinants that lead to these disparities and to create new and improved
treatment options for adenocarcinomic NSCLC. As part of the research for this thesis,
three novel photosensitive agents were synthesized, purified, and characterized for
potential use in photodynamic therapy. These potential PDT agents were then tested on
an adenocarcinomic non-small cell lung cancer cell line.

Photodynamic Therapy (PDT)
Introduction to PDT
One potential treatment option for patients with non-small cell lung cancer is
Photodynamic therapy (PDT). Photodynamic therapy is a treatment where a patient is
injected with a photosensitive agent that preferentially accumulates in tumor tissue. When
the tumor is exposed to light for a certain amount of time, the photosensitizer is activated,
and selectively destroys the tumor. The process of photodynamic therapy is thought to
occur via a type II photochemical reaction. Light excites a photosensitive electron which
goes through intersystem crossing to form a triplet state. This excited electron reacts with
oxygen, creating singlet oxygen that is able to destroy cancer cells.8
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Figure 1. Photodynamic Therapy

Advantages of Photodynamic Therapy
Traditional cancer therapy, such as chemotherapy with cisplatin, has a high
toxicity, undesirable side effects, and drug resistance.9 Because traditional cancer therapy
targets all rapidly dividing cells, patients often lose their hair and have gastrointestinal
issues. Other traditional cancer therapy includes surgical resection.
Photodynamic therapy presents an alternative treatment option for lung cancer. It
is non-invasive and would not require hospitalization. For treating lung cancer using
PDT, a patient could be injected with a photosensitizer, and an endoscope with a light
could be passed through the mouth to shine light on tumor tissue in the lungs.
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Figure 2. Lung Anatomy10
Note. For the National Cancer Institute © (2006) Terese Winslow LLC, U.S. Govt. has
certain rights

Photodynamic therapy could potentially limit surgical procedures and have less
burdensome side effects. This would allow for patients to return to their normal activities
more quickly after treatment including returning to work.11 Photodynamic therapy could
also be used as a combination therapy for lung cancer or as a palliative treatment for
patients who are not able to have surgery or radiation therapy.12 Additionally,
photodynamic therapy would be less costly. The average cost for traditional cancer
therapy including surgery, chemotherapy, and radiation would be approximately
$33,360.13 In contrast, a single round of photodynamic therapy depending on the type and
severity of the cancer, could be between $100 and $4,000 for a single treatment to
approximately $10,000 for a series of treatments.14 Most importantly, PDT could
potentially increase the survival rates for lung cancer patients, therefore lessening the
lung cancer disparities that exist in healthcare.
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Photosensitive agents in PDT
Photodynamic therapy requires a photosensitive agent. There are several
tetrapyrrole structures that make ideal photosensitive agents, including porphyrins. A
porphyrin is a planar molecule with alternating double bonds (Figure 3). These double
bonds allow for the absorption of light, leading to the creation of singlet oxygen which
destroys tumor tissue. Additionally, porphyrins are advantageous as potential PDT agents
because their core can be metallated and the peripheral functional groups can be modified.
A common example of a porphyrin core is found in hemoglobin found in the blood (Figure
4). The heme porphyrin has an iron atom in the core and various substituents on the
periphery.

Figure 3. Porphyrin Core
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Figure 4. Hemoglobin Molecule with Porphyrin Core

Current Clinical Applications
There are several current photosensitizers currently in use. One of these
photosensitizers is Photofrin, which has a porphyrin core (Figure 5). It is used for
endobronchial cancer. First generation photosensitizers such as Photofrin, cause side
effects such as lasting skin photosensitivity because they are not rapidly cleared from the
body.12 Thus, the creation of new second generation photosensitizers is necessary. One
example of a second-generation photosensitizer is taloporfin (Figure 6). It has a chlorin
core and has been approved for use in Japan for the treatment of lung cancer.
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Figure 5. Photofrin15

Figure 6. Taloporfin15

INTRODUCTION TO PROJECT
This research focused on synthesizing novel water-soluble porphyrin compounds
for use as photosensitive agents in PDT for the treatment of lung cancer. The periphery of
the porphyrin core can be modified with various substituents to assist with watersolubility and cytotoxicity. In this research, the core of 5, 10, 15, 20-tetrakis(4carboxyphenyl)porphyrin, H2TPPC, was modified with the attachment of L-threoninol to
create the novel H2TPP-Thr. The core was also modified with
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tris(hydroxymethyl)aminomethane, TRIS, to synthesize H2TPP-TRIS. Additionally,
ZnTPPC was modified using TRIS to form the novel ZnTPP-TRIS.
L-threoninol and TRIS both contain primary amine groups, -NH2, which allow for
their attachment with the porphyrin core via an acid chloride intermediate. TRIS contains
three alcohol, -OH, groups, while L-threoninol contains two alcohol, -OH groups. It was
thought that the addition of -OH groups may allow for greater water solubility and
increase the efficacy of the porphyrin product in killing cells. In addition, TRIS is
biologically friendly and used for buffering,16 so it was thought that the attachment of
TRIS would not increase the cytotoxicity of the porphyrin product without the presence
of light.
Each compound was purified by column chromatography using both Sephadex
LH-20 and Sephadex G-50. Additionally, nuclear magnetic resonance (NMR), infrared
(IR), and UV-visible spectroscopies (UV-vis) were used to characterize each compound.
Purity of the final products was determined using high performance liquid
chromatography (HPLC). Finally, compounds were tested using MTT assays to
determine cell viability in both light and dark conditions on an A549 non-small cell lung
cancer cell line. It is important that photosensitive agents, such as these porphyrin
products, cause minimal to no cytotoxicity in the absence of light.
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METHODS
Synthesis of Porphyrin Compounds
Formation of H2TPPC (3)
H2TPPC, 5, 10, 15, 20-tetrakis(4-carboxyphenyl)porphyrin, served as the starting
material for each reaction. A 3.00 g amount of 4-carboxybenzaldehyde (2) and 1.5 mL of
pyrrole (1) were added to a 500 mL round bottom flask with approximately 200 mL of
propionic acid and a stir bar (Figure 7). The flask was wrapped in aluminum foil to
prevent side products. The reaction was then heated to reflux and refluxed for one hour.
The reaction was cooled to room temperature, before being covered with parafilm and put
in a -20 °C freezer overnight.
The product of the reaction was then vacuum filtered using a medium sintered
glass fritted filter. Dichloromethane, DCM, was used to wash the product three times to
remove impurities. The H2TPPC final product was then transferred into a vial and dried
for 30 minutes in the oven.

Figure 7. Reaction 1. 4-carboxybenzaldehyde (2) reacted with pyrrole (1) in
propionic acid solution to form H2TPPC (3).
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Formation of the Acid-Chloride Intermediate (4)
To form the acid-chloride intermediate, 0.15 g of the starting material, H2TPPC
(3), was dissolved in 20 mL of dried dimethylformamide (DMF) in a clean, oven dried,
100 mL round bottom flask. A syringe was used to add 0.2 mL of thionyl chloride,
SOCl2, to the flask before the flask was capped with a rubber septum (Figure 8). The
reaction was stirred under a constant flow of nitrogen for one hour. Afterward, the DMF
was evaporated off using a rotovap, and the flask was placed under vacuum overnight.

Figure 8. Reaction 2. H2TPPC (3) reacts with SOCl2 in DMF, forming an acid chloride
porphyrin (4).
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Formation of the Final Products
H2TPP-Thr (5)
Following the initial formation of the acid-chloride intermediate, the final
product, H2TPP-Thr (5), was synthesized by using the amine L-threoninol (Figure 9). LThreoninol was dried overnight and then 0.3 g of L-threoninol was dissolved in freshly
distilled methanol and this solution was transferred to the round bottom flask containing
the acid-chloride intermediate. The reaction was placed back under nitrogen and stirred
for one hour. The methanol was then evaporated to yield the final H2TPP-Thr (5) product.
A small amount of product was placed in MilliQ H2O to test for water solubility.

Figure 9. Reaction 4. The acid chloride porphyrin (4) reacts with L-threoninol in
methanol to form H2TPP-Thr, the final product (5).
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H2TPP-TRIS (6)
To create the final product, H2TPP-TRIS (6), tris (hydroxymethyl)aminomethane,
TRIS, was first oven dried overnight. The TRIS, 0.37 g, was dissolved in freshly distilled
methanol, and transferred to the round bottom flask containing the acid chloride
intermediate (Figure 10). The reaction was kept under nitrogen and stirred for one hour.
The methanol was evaporated, and the final product was tested for water solubility in
MilliQ H2O.

Figure 10. Reaction 3. The acid chloride porphyrin (4) reacts with TRIS in methanol to
form H2TPP-TRIS, the final product (6).
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ZnTPP-TRIS (8)
To create the ZnTPP-TRIS, 1.00 g of the H2TPPC starting material (3) and 0.36 g
of ZnCl2 were put in a flask. DMF was added and the reaction was heated to reflux and
refluxed for 3 hours while being covered in aluminum foil. The DMF was evaporated.
The remaining product was dissolved in methanol, MeOH, and then filtered using a
sintered glass filter. The filtrate was rotovapped. The product was filtered and washed
with DCM to obtain the ZnTPPC solid (7) (Figure 11).

Figure 11. Reaction 5. H2TPPC (3) reacts with ZnCl2 in DMF to form ZnTPPC (7).

ZnTPPC (7) in the amount of 0.15 g was dissolved in 50 mL of tetrahydrofuran,
THF. Then, 0.32 g of TRIS was dissolved in DI H2O and added to the flask along with
0.23 g of HOBT. The flask was placed in an ice bath and stirred for 15 minutes. A 0.36 g
amount of DCC was added to the flask and then the flask was removed from the ice bath
and allowed to warm to room temperature. The reaction was then stirred for 3 hours at
room temperature. The solvent was then removed by rotovap. The final product (8) was
placed in MilliQ H2O to test for water solubility.
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Figure 12. Reaction 6. ZnTPPC (7) reacts with TRIS in THF/DI
H2O/HOBT/DCC forming ZnTPP-TRIS, the final product (8).

Each reaction was done three times to ensure repeatability, and obtain enough
working product.
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Purification of Porphyrin Compounds
LH-20 and G-50 column chromatography
A 50:50 MeOH:H2O mixture was added to the flask to dissolve the final product.
Syringe filtration was performed using a 0.45 μm nylon syringe filter and the filtrate was
added to a chromatography column packed with Sephadex LH-20. The desired product
was eluded with a 50:50 MeOH:H2O mixture. Only the desired purple product coming
off the column was collected. The MeOH:H2O mixture was then rotovapped to obtain the
purified, solid porphyrin product. Following LH-20 purification, the solid porphyrin
product was dissolved in Milli-Q water. The solution was then run through a
chromatography column containing Sephadex G-50. Each of the final purified products
were collected and the H2O was evaporated. This purification process was done for each
of the desired final products.

Figure 13. LH-20 and G-50 Chromatography Columns
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Characterization
Infrared Spectroscopy (IR)
Background
The bonds in compounds can stretch and bend when excited by infrared radiation,
which will cause them to vibrate. This is analogous to a spring that can be stretched or
compressed and vibrates when it is released. Upon excitation with infrared radiation, the
bonds in compounds will absorb differing frequencies due to their energetic properties.
The IR spectrum measures these frequencies in wavenumbers, cm-1. The energy differs
depending on the type of bond, as some bonds require more energy to be stretched or
compressed. This allows for the determination of functional groups within a compound.17
Results
IR spectra was run on both the free amines and final porphyrin products (Figures
14-18). Spectra for the free amines show a sharp N-H stretch around 3300 cm-1. The
absorption bands are characteristic of primary amines. In coupling to the amine
porphyrin core for H2TPP-Thr, H2TPP-TRIS, and ZnTPP-TRIS, several other absorption
bands appear. There is a broad O-H stretch around 3300 cm-1, a C=O stretch around 1700
cm-1, and amide I, II, and III bands. The appearance of the amide bands is one of the
strongest demonstrations that the free amine has been attached to the porphyrin core. The
amide I band appears between 1600-1500 cm-1. The amide II band is between 1650-1515
cm-1 due to N-H bending. The amide III band appears at around 1379 cm-1 due to a C-N
stretch. In the final porphyrin product, the N-H stretch is not seen due to the broad O-H
stretch, further confirming the attachment of the free amine to the porphyrin core.
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Figure 14. IR Spectrum for L-Threoninol

Figure 15. IR Spectrum for H2TPP-Thr
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Figure 16. IR Spectrum for tris(hydroxymethyl)aminomethane

Figure 17. IR Spectrum for H2TPP-TRIS
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Figure 18. IR Spectrum for ZnTPP-TRIS
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UV-Vis Spectroscopy
Background
Conjugated π bonds are characteristic of porphyrin structures. In ultravioletvisible (UV-Vis) spectroscopy, π electrons are excited to higher energy levels when
irradiated with UV-Vis light.17 Light from the spectrophotometer passes through a
cuvette containing the porphyrin sample dissolved in the water solvent. The intensity of
the light that passes through at varying wavelengths are compared and a spectrum is
generated giving the absorbance at each wavelength for the porphyrin compound. Beer’s
Law is then utilized to calculate the molar absorptivity, ε, of the porphyrin compound.
UV-Vis allows for the characterization of compounds due to individual compounds
having unique molar absorptivity. For the scope of this research, a Soret band
characteristic of porphyrin compounds was desired at ca. 415 nm for the non-metallated
porphyrins and ca. 423 nm for the metallated zinc porphyrins. Additionally, Q bands
were expected to be seen in the final product spectra due to the inherent degenerate
transitions.18
Results
The following spectra (Figures 19-21) confirmed the presence of a highly
conjugated system. Additionally, it confirmed structural elements such as the presence of
zinc in ZnTPP-TRIS shown through the shifting of the wavelength of absorbance for the
Soret band. The Soret bands are shown below in grey, while Q bands are in white. The
Soret band for the non-metallated compounds, H2TPP-Thr and H2TPP-TRIS (Figure 1920) appeared at a 415 nm wavelength, while the Soret band for the ZnTPP-TRIS (Figure
21) was at a wavelength of 421 nm.
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H2TPP-Thr
λ, (nm)
Molar absorptivity coefficient (mM-1cm-1)
415
281
518
11.9
555
6.9
580
5.3
636
3.3
Table 1. UV-VIS Molar absorptivity coefficients for H2TPP-Thr spectral peaks
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Figure 19. UV-VIS Spectrum for H2TPP-Thr
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H2TPP-TRIS
λ, (nm)
Molar absorptivity coefficient (mM-1cm-1)
415
330
518
11
555
6.7
581
4.8
636
3.2
Table 2. UV-VIS Molar absorptivity coefficients for H2TPP-TRIS spectral peaks
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Figure 20. UV-VIS Spectrum for H2TPP-TRIS
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ZnTPP-TRIS
λ, (nm)
Molar absorptivity coefficient (mM-1cm-1)
421
330
558
16.1
598
8.6
Table 3. UV-VIS Molar absorptivity coefficients for ZnTPP-TRIS spectral peaks
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Figure 21. UV-VIS Spectrum for ZnTPP-TRIS
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Nuclear Magnetic Resonance Spectroscopy (NMR)
Background
Nuclear Magnetic Resonance Spectroscopy (NMR) is a type of magnetic
spectroscopy that allows for the characterization of compounds on the basis of their
nuclei’s spin and magnetic dipole. Different nuclei within a compound have differing
chemical environments leading to different total magnetic fields. As a result, nuclei
absorb varying amounts of magnetic field frequency and show different chemical shifts.17
Results
NMR spectra were obtained on the final porphyrin products and each of the free
amines shown in Figures 22-26. Water eliminated fourier transform (WEFT) was utilized
to suppress the water signal and allow for better spectral visualization for each of the
final porphyrin products. The final porphyrin products showed chemical shifts
characteristic of both the porphyrin ring’s aromatic hydrogens ca. 8 ppm as well as the
aliphatic hydrogens characteristic of the free amine.
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Figure 22. NMR spectrum for L-threoninol

Figure 23. NMR spectrum for WEFT H2TPP-Thr

Figure 24. NMR spectrum for tris (hydroxymethyl)aminomethane
31

Figure 25. NMR spectrum for WEFT H2TPP-TRIS

Figure 26. NMR spectrum ZnTPP-TRIS
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High Performance Liquid Chromatography (HPLC)
High Performance Liquid Chromatography (HPLC) is utilized to separate,
identify, and quantify soluble compounds. In HPLC, high pressure is used to create a
flow for liquid chromatography to take place in a packed column. HPLC allows for the
determination of the purity of a sample.19
The purity of each porphyrin product was determined by dissolving the product in
Milli-Q H2O and using a Hamilton PRP-1 5µm 4.1 x 150 mm column. A 100%
acetonitrile solvent was used at a flow rate of 1.00 mL/min. The H2TPP-Thr had a purity
of 98.9, the H2TPP-TRIS had a purity of 98.6%, and the ZnTPP-TRIS had a purity of
97.8%.

Figure 27. HPLC Trace for ZnTPP-TRIS

Compound

Purity

H2TPP-Thr

98.9%

H2TPP-TRIS

98.6%

ZnTPP-TRIS

97.8%

Table 4. HPLC Purities for final porphyrin products
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Cytotoxicity Testing
Background
An MTT assay is a colorimetric assay utilized for measuring the metabolic
activity of cells, and therefore their viability. An MTT assay allows for the determination
of the efficacy of the porphyrin compound by measuring the interruption of cell
metabolism and therefore the killing of cells. In an MTT assay, metabolically active cells
reduce yellow tetrazolium salt to purple formazan crystals. These crystals are then
dissolved, and the absorbance can be measured with a spectrophotometer. The darker
purple corresponds to the more metabolically active cells. Thus, cells exposed to light
with no porphyrin compound or lesser concentration should have greater metabolic
activity or more living cells. Porphyrin compounds with greater efficacy should have
decreased metabolic activity when exposed to light, preferably at small concentrations.
Cells containing the porphyrin compound that are not exposed to light, should have
minimal cytotoxicity, as the porphyrin compound should only be activated when exposed
to light.20

MTT Assay Methodology
A549 cells from the American Type Culture Collection (ATCC) were plated on
two 96-well plates and cultured with MEM growth medium. Varying concentrations of
the porphyrin compound being tested were added after cells were ~25% confluent, with
each concentration being replicated in eight of the wells. The plates were wrapped in
aluminum foil to prevent light contamination and were placed back in the incubator.
After approximately 22 hours, one of the plates was exposed to white light (0.5 J/cm2) for
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20 minutes while the other plate was kept in the dark. The plates were then incubated
again. After 72 hours, MTT reagent was placed on the cells for 3 hours to allow time for
the purple formazan product to form. The formazan crystal product was then dissolved in
DMSO. A spectrophotometer was used read at wavelengths of 570 nm and 630 nm. The
difference between the two wavelengths was used to quantify and compare the amount of
purple coloring, indicating the cell’s viability, and thus porphyrin compound toxicity.

Figure 28. MTT Assay for ZnTPP-TRIS (8) in last 6 columns with purple indicating
greater cell metabolism

MTT Assay Results
Six MTT assay trials were done to test the cytotoxicity of H2TPP-Thr. A
preliminary trial used concentrations of 0, 1, 3, 10, and 30 µM. The second and third
trials used concentrations of 0, 50, 75, 100, 125, and 150 µM, while the fourth through
sixth trials utilized concentrations of 0, 100, 150, 200, and 250 µM. It was determined
that H2TPP-Thr had a lethal dose, the concentration where 50% of the cells are killed,
LD50, ca. 200 micromolar (Figure 29).
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Figure 29. Spectrophotometric MTT assay results for H2TPP-Thr (5)

Five trials were done to test the cytotoxicity of H2TPP-TRIS. The first trial
utilized concentrations of 0, 1, 3, 10, 30, and 100 µM concentrations. The second through
fifth trials utilized 0, 25, 50, 75, 100, and 125 µM. As seen in Figure 30, H2TPP-TRIS
has an LD50 of approximately 100 µM.
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Figure 30. Spectrophotometric MTT assay results for H2TPP-TRIS (6)
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A preliminary trial of ZnTPP-TRIS was done utilizing 0, 1, 3, 10, 30, 100, and
150 µM. The LD50 was around 50 micromolar. This compound was tested further during
the summer of 2021 using 0, 13, 16, 20, 23, and 26 µM concentrations. This second trial
showed the LD50 may be as low as 16 µM. Further testing is needed to confirm this lower
LD50. In both trials, the LD50 was lower than that of the non-metallated porphyrin,
H2TPP-TRIS.
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Figure 31. Spectrophotometric MTT assay results for preliminary ZnTPP-TRIS trial (8)
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Figure 32. Spectrophotometric MTT assay results for additional ZnTPP-TRIS trial (8)
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CONCLUSIONS
Three novel water-soluble porphyrin compounds were developed for potential use
as photosensitive agents in photodynamic therapy. Two free amines, thought to be
biologically friendly were successfully attached to the porphyrin core. All three
compounds showed minimal to no cytotoxicity in the dark. This result is promising
because the porphyrin products should only be killing cells when exposed to light.
H2TPP-Thr had an LD50 of ca. 200 µM and H2TPP-TRIS showed an LD50 of ca. 100 µM
when exposed to light. H2TPP-TRIS showed higher cytotoxicity at lower concentrations
than H2TPP-Thr. This could potentially be due to greater water solubility due to an
additional -OH group. Finally, preliminary results show the LD50 of ZnTPP-TRIS to be
between 15 and 50 µM when exposed to light. Further testing is necessary to confirm
these preliminary results. ZnTPP-TRIS showed greater toxicity at lower concentrations
than H2TPP-TRIS, showing promise that metallized porphyrin compounds such as
ZnTPP-TRIS may have greater efficacy as PDT agents. New, second generation PDT
agents such as these synthesized, may help to eliminate health disparities in the treatment
of lung cancer. The further implementation of PDT in the treatment of lung cancer could
limit surgical procedures and side effects. It could also minimize treatment costs, which
is particularly important for patients of low socio-economic status. It could also lead to
better survival outcomes which could help to close the health disparity gap for minority
groups like African Americans, Asian Americans, Native Americans and
underrepresented groups like women.
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FUTURE WORK
In the future, further testing is needed to confirm the true LD50 value for ZnTPPTRIS. The synthesis and comparison of the cytotoxicity in the presence and absence of
light of additional metallated and non-metallated porphyrins using the same amine
coupled to the periphery of the porphyrin core. This is needed to generalize if metallated
porphyrins have greater efficacy than non-metallated porphyrins for a particular cancer
cell line. These compounds should also be tested on other cancer cell lines. Additionally,
these porphyrin compounds should have further cytotoxicity testing using red light
(Figure 32), rather than the white light previously used. Red light is classically used in
vivo for PDT treatment, as it has a greater wavelength, and thus increased penetration
depth of tumor tissue.21 If the novel water-soluble porphyrin compounds show similar or
greater efficacy using red light, they can be tested in vivo with mice in collaboration with
Dr. Theresa Busch at the University of Pennsylvania School of Medicine.

Figure 33. Red light filter.
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